ЕКСПРЕСІЯ РЕЦЕПТОРА ПРОГРАМОВАНОЇ КЛІТИННОЇ ЗАГИБЕЛІ У ХВОРИХ НА РАК ЕНДОМЕТРІЯ З МЕТАБОЛІЧНИМИ ПОРУШЕННЯМИ
Aim: To study the expression of the programmed cell death receptor (PD-1) and its ligand (PD-L1) by immunocompetent cells in endometrial cancer patients with metabolic disorders. Materials and Methods: Populations and subpopulations of lymphocytes were analyzed by flow cytometry. Antibodies against...
Збережено в:
| Дата: | 2023 |
|---|---|
| Автори: | , , , , , |
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
PH Akademperiodyka
2023
|
| Теми: | |
| Онлайн доступ: | https://exp-oncology.com.ua/index.php/Exp/article/view/2023-1-4 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Experimental Oncology |
Репозитарії
Experimental Oncology| Резюме: | Aim: To study the expression of the programmed cell death receptor (PD-1) and its ligand (PD-L1) by immunocompetent cells in endometrial cancer patients with metabolic disorders. Materials and Methods: Populations and subpopulations of lymphocytes were analyzed by flow cytometry. Antibodies against CD279 were used to detect PD-1 on the CD4+ and CD8+ T cells. Antibodies against CD14 and CD274 were used to detect PD-L1 on monocytes. Results: In patients with severe metabolic disorders, the expression of PD-1 on CD8+ and CD4+ lymphocytes and the expression of the corresponding PD-L1 on CD14+ cells before treatment and after radiation therapy were higher than in the control group. Conclusion: Theincreased expression of PD-1 and PD-L1 receptors by immunocompetent cells can be considered a new prognostic marker in endometrial cancer patients with morbid obesity. |
|---|